Get the Stockscreener App
8.96
3.23%
0.28
After Hours:
8.96
Actuate Therapeutics Inc stock is traded at $8.96, with a volume of 88,233.
It is up +3.23% in the last 24 hours and up +23.42% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$8.68
Open:
$8.69
24h Volume:
88,233
Relative Volume:
1.96
Market Cap:
$175.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.11%
1M Performance:
+23.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$8.673
$9.38
1-Week Range:
$8.35
$9.39
52-Week Range:
$5.51
$10.16
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ACTU | 8.96 | 175.00M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Actuate Therapeutics Inc Stock (ACTU) Latest News
FDA OKs Ninlotinib Tablets With No Mealtime Restrictions for CML - www.oncnursingnews.com/
FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma - www.oncnursingnews.com/
FDA grants rare disease status to Actuate's Ewing sarcoma drug By Investing.com - Investing.com Australia
FDA grants rare disease status to Actuate's Ewing sarcoma drug - Investing.com India
Actuate Therapeutics : FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - Marketscreener.com
Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - MarketWatch
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - The Manila Times
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.8%Time to Sell? - MarketBeat
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development - The Manila Times
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - GlobeNewswire
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - GlobeNewswire Inc.
Global Secondary Myelofibrosis Therapeutics Market Poised to Reach USD 2.74 Million by 2033 with a 6 - PharmiWeb.com
Pancreatic Cancer Market Size is Set for Rapid Growth as - openPR
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
IPO Roundup: zSpace, Actuate Therapeutics and more - MSN
Bone Metastasis in Solid Tumors Market Expected to Experience - openPR
Quarterly IPOs Climb Back Above $1bn - In Vivo
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.5%Here's What Happened - MarketBeat
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
Actuate Announces Scientific Reports Publication on - GlobeNewswire
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Yahoo Finance
Bone metastasis in Solid Tumor Market Size is Set for Rapid Growth - openPR
Achilles Therapeutics Announces Strategic Update - StockTitan
Cintas (NASDAQ:CTAS) PT Raised to $225.00 - Defense World
Cintas (NASDAQ:CTAS) PT Raised to $225.00 at Truist Financial - MarketBeat
Capricor rises as it expands deal with Nippon Shinyaku - The Pharma Letter
Capricor Therapeutics Secures Lucrative European Partnership - TipRanks
Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - StockTitan
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga
Actuate Announces Upcoming Presentation on Initial Data on - GlobeNewswire
Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma - OncLive
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Behind the Bell: Actuate Therapeutics - Nasdaq
Elraglusib Granted FDA Orphan Drug Status in Soft Tissue Sarcoma - AJMC.com Managed Markets Network
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas - GlobeNewswire
Actuate gains FDA orphan drug status for cancer treatment - Investing.com
Biopharma financings near $78B, almost double last year’s value - BioWorld Online
Elraglusib shows promise in Ewing sarcoma trial - Investing.com
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewswire
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Stock Quotes, Forecast and News Summary - Benzinga
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs - Scrip
Actuate Therapeutics’ $22,4 Million Initial Public Offering - Global Legal Chronicle
Actuate Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Actuate Therapeutics Rings the Opening Bell - Nasdaq
Wheeling Native Daniel Schmitt To Ring Wall Street Bell - Wheeling Intelligencer
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - GlobeNewswire
Actuate Therapeutics appoints new accounting firm By Investing.com - Investing.com Australia
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):